

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250



ASX Release

20 March 2024

ALA-101 + ONCARLYTICS COLLABORATION UPDATE

MELBOURNE, AUSTRALIA 20 March 2024: Arovella Therapeutics Ltd (ASX: ALA) announces that the partnership to combine ALA-101 and onCARlytics has ended.

On 26 September 2022, Arovella announced that it had entered into a research collaboration with Imugene to combine Arovella's ALA-101 with Imugene's onCARlytics platform.¹ Imugene has advised Arovella that it no longer wishes to continue the collaboration, which will be terminated with immediate effect. As such, *in vivo* data for the combination of ALA-101 and onCARlytics will no longer be generated.

The termination of the collaboration will not impact Arovella's development of ALA-101 for CD19-positive blood cancers. Since initiating the Imugene collaboration 18 months ago, Arovella has also secured a globally leading target for gastric and pancreatic cancers (claudin 18.2) and its IL-12-TM armouring technology, which it will continue to develop for a range of solid tumours. There is no financial impact from the cessation of the collaboration for Arovella.

Release authorised by the Board of Directors of Arovella Therapeutics Limited.

Dr Michael Baker

Chief Executive Officer & Managing Director

Arovella Therapeutics Ltd

Tel +61 (0) 403 468 187

investor@arovella.com

¹ 26 September 2022: "New preclinical trial of Arovella's iNKT cell therapy platform and Imugene's onCARlytics (CF33-CD19) platform to explore potential in solid tumours."

NOTES TO EDITORS:**About Arovella Therapeutics Ltd**

Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Additional tumour targeting technologies are anticipated to be used in conjunction with Arovella's iNKT cell therapy platform. Arovella's lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTCR) that targets α -GalCer bound CD1d, another antigen found on the surface of several cancer types. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient.

Glossary: **iNKT cell** – invariant Natural Killer T cells; **CAR** – Chimeric Antigen Receptor that can be introduced into immune cells to target cancer cells; **TCR** – T cell receptors are a group of proteins found on immune cells that recognise fragments of antigens as peptides bound to MHC complexes; **B-cell lymphoma** – A type of cancer that forms in B cells (a type of immune system cell); **CD1d** – Cluster of differentiation 1, which is expressed on some immune cells and cancer cells; **α GalCer** – alpha-galactosylceramide is a specific ligand for human and mouse natural killer T cells. It is a synthetic glycolipid.

For more information, visit www.arovella.com

This announcement contains certain statements which may constitute forward-looking statements or information ("forward-looking statements"), including statements regarding negotiations with third parties and regulatory approvals. These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding the actions of third parties and financial terms. These factors and assumptions are based upon currently available information, and the forward-looking statements herein speak only of the date hereof. Although the expectations and assumptions reflected in the forward-looking statements are reasonable in the view of the Company's directors and management, reliance should not be placed on such statements as there is no assurance that they will prove correct. This is because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; the risk associated with foreign currencies; and risk associated with securities market volatility. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by Australian securities laws and ASX Listing Rules.